Nearly 30 years ago, Children’s Hospital Los Angeles supported one of the first clinical trials for a pioneering stem cell gene therapy for children with a life-threatening form of severe combined immunodeficiency (SCID). Called ADA-SCID–a type of “bubble boy disease” caused by mutations in the adenosine deaminase (ADA) gene–this rare disorder leaves babies with virtually no immune system.
